Should I buy or sell Science 37 stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Science 37 in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" SNCE shares. View SNCE analyst ratings or view top-rated stocks .

What is Science 37's stock price target for 2024?

1 brokers have issued 12-month target prices for Science 37's stock. Their SNCE share price targets range from $1.00 to $1.00. On average, they anticipate the company's share price to reach $1.00 in the next twelve months. This suggests a possible upside of 300.0% from the stock's current price. View analysts price targets for SNCE or view top-rated stocks among Wall Street analysts .

How have SNCE shares performed in 2023?

Science 37's stock was trading at $0.4152 at the beginning of 2023. Since then, SNCE stock has decreased by 39.8% and is now trading at $0.25. View the best growth stocks for 2023 here .

Are investors shorting Science 37?

Science 37 saw a increase in short interest in November. As of November 15th, there was short interest totaling 1,630,000 shares, an increase of 50.9% from the October 31st total of 1,080,000 shares. Based on an average daily trading volume, of 209,600 shares, the days-to-cover ratio is currently 7.8 days. Currently, 2.1% of the shares of the stock are short sold. View Science 37's Short Interest .

When is Science 37's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 4th 2024. View our SNCE earnings forecast .

How were Science 37's earnings last quarter?

Science 37 Holdings, Inc. (NASDAQ:SNCE) issued its earnings results on Tuesday, November, 7th. The company reported ($0.08) earnings per share for the quarter. The company had revenue of $14.89 million for the quarter, compared to the consensus estimate of $14.70 million. Science 37 had a negative net margin of 206.86% and a negative trailing twelve-month return on equity of 83.09%.

Who are Science 37's major shareholders?

Science 37's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Boston Partners (1.19%) and Kent Lake Capital LLC (0.91%). View institutional ownership trends .

How do I buy shares of Science 37?

Shares of SNCE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Science 37 Stock Price, News & Analysis (NASDAQ:SNCE)

$0.25

0.00 (0.00%)

(As of 12/4/2023 ET)

Compare

Today's Range: $0.23
▼
$0.26
50-Day Range: $0.24
▼
$0.42
52-Week Range: $0.19
▼
$0.69

Volume: 367,158 shs
Average Volume: 788,613 shs
Market Capitalization: $29.85 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $1.00

Science 37 MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 300.0% Upside
$1.00 Price Target
Short Interest: Bearish
2.06% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.55) to ($0.40) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.97 out of 5 stars

Medical Sector

568th out of 952 stocks

Commercial Physical Research Industry

10th out of 12 stocks

3.5

Analyst's Opinion

Consensus Rating
Science 37 has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $1.00, Science 37 has a forecasted upside of 300.0% from its current price of $0.25.
Amount of Analyst Coverage
Science 37 has received no research coverage in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
2.06% of the float of Science 37 has been sold short.
Short Interest Ratio / Days to Cover
Science 37 has a short interest ratio ("days to cover") of 7.8.
Change versus previous month
Short interest in Science 37 has recently increased by 50.93%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Science 37 does not currently pay a dividend.
Dividend Growth
Science 37 does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for SNCE.

1.9

News and Social Media Coverage

News Sentiment
Science 37 has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.76 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Science 37 this week, compared to 1 article on an average week.
Search Interest
Only 4 people have searched for SNCE on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
MarketBeat Follows
2 people have added Science 37 to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Science 37 insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 6.80% of the stock of Science 37 is held by insiders.
Percentage Held by Institutions
40.67% of the stock of Science 37 is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Science 37 are expected to grow in the coming year, from ($0.55) to ($0.40) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Science 37 is -0.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Science 37 is -0.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Science 37 has a P/B Ratio of 0.30. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Science 37 Stock (NASDAQ:SNCE)

Science 37 Holdings, Inc. engages in patient-centric clinical trial activities in North Carolina. Its platform enables modern and digital approaches to clinical research, including the patient and trial investigators, nurses, coordinators, and sponsors, standardize evidence generation, and harmonize data. The company's platform also provides specialized networks of patient communities, telemedicine investigators, mobile nurses, remote coordinators, and connected devices for orchestrating clinical trials; and extensive configuration to support virtually any phase of clinical study and therapeutic area. In addition, the company licenses its proprietary hosted technology platform to various life science institutions. It serves large and mid-sized pharmaceutical companies, contract research organizations, academic institutions, and biotech companies. Science 37 Holdings, Inc. was founded in 2014 and is based in Research Triangle Park, North Carolina.

SNCE Stock Price History

30 days | 90 days | 365 days | Advanced Chart

SNCE Stock News Headlines

November 12, 2023 | finance.yahoo.com

Science 37 Holdings, Inc. (NASDAQ:SNCE) Q3 2023 Earnings Call Transcript

November 11, 2023 | finance.yahoo.com

It's Down 28% But Science 37 Holdings, Inc. (NASDAQ:SNCE) Could Be Riskier Than It Looks

December 4, 2023 | DTI Trader (Ad)

New CBOE “special perk” helps traders target income every weekend

You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.

November 8, 2023 | markets.businessinsider.com

Analysts’ Top Healthcare Picks: Science 37 (SNCE), Guardant Health (GH)

November 7, 2023 | msn.com

Science 37 reports mixed Q3 earnings; initiates Q4 and updates FY23 outlook

November 7, 2023 | finance.yahoo.com

Science 37 Reports Third Quarter 2023 Financial Results

November 7, 2023 | finance.yahoo.com

Science 37 Holdings Inc (SNCE) Reports Q3 2023 Financial Results

November 6, 2023 | markets.businessinsider.com

What Wall Street expects from Science 37's earnings

December 4, 2023 | Wealthpress (Ad)

Trading Experts Call It “The Perfect Tesla Trade”

Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.

October 24, 2023 | finance.yahoo.com

Science 37 to Report Third Quarter 2023 Financial Results on November 7, 2023

September 21, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Inventiva (IVA) and Science 37 (SNCE)

September 20, 2023 | finance.yahoo.com

Science 37 Chief Delivery Officer, Darcy Forman, Named to Prestigious PharmaVoice 100 List

September 12, 2023 | finance.yahoo.com

Science 37 Named Market Leader for Global Decentralized Clinical Trials by Frost & Sullivan

September 5, 2023 | finance.yahoo.com

Science 37 to Participate in H.C. Wainwright 25th Annual Global Investment Conference

August 15, 2023 | finance.yahoo.com

Science 37 Recognized as Best Digital Health Solution Nominee at 2023 Prix Galien USA Awards

August 13, 2023 | barrons.com

Science 37 Holdings Inc.

August 11, 2023 | finance.yahoo.com

Increasing losses over year doesn't faze Science 37 Holdings (NASDAQ:SNCE) investors as stock rallies 122% this past week

August 9, 2023 | investing.com

Science 37 Holdings (SNCE) Earnings Dates & Reports

August 8, 2023 | finanznachrichten.de

Science 37, Inc.: Science 37 Reports Second Quarter 2023 Financial Results

August 8, 2023 | msn.com

Science 37 GAAP EPS of -$0.17 misses by $0.02, revenue of $15.35M beats by $2.78M

August 8, 2023 | finance.yahoo.com

Science 37 Reports Second Quarter 2023 Financial Results

August 7, 2023 | benzinga.com

Science 37 Hldgs Earnings Preview

July 25, 2023 | finance.yahoo.com

Science 37 to Report Second Quarter 2023 Financial Results on August 8, 2023

July 11, 2023 | finance.yahoo.com

Synlogic Partners with Science 37 on Pivotal Study for Investigational Drug for Phenylketonuria (PKU)

July 11, 2023 | finance.yahoo.com

Synlogic Partners with Science 37 on Pivotal Study for Investigational Drug for Phenylketonuria (PKU)

July 8, 2023 | finanznachrichten.de

Science 37, Inc.: Science 37 Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

May 18, 2023 | finance.yahoo.com

Science 37 Wins 2023 MedTech Breakthrough Award for "Best Overall Clinical Trial Platform"

See More Headlines

Receive SNCE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Science 37 and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/07/2023
Today: 12/04/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/04/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Commercial physical research
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:SNCE
CUSIP: N/A
CIK: 1819113
Web: www.lifesciacquisition.com
Phone: 984-377-3737
Fax: N/A
Employees: 460
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $1.00
High Stock Price Target: $1.00
Low Stock Price Target: $1.00
Potential Upside/Downside: +299.8%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.07)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-50,990,000.00
Net Margins: -206.86%
Pretax Margin: -207.00%
Return on Equity: -83.09%
Return on Assets: -61.58%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.17
Quick Ratio: 4.17

Sales & Book Value

Annual Sales: $70.15 million
Price / Sales: 0.43
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.83 per share
Price / Book: 0.30

Miscellaneous

Outstanding Shares: 119,400,000
Free Float: 111,278,000
Market Cap: $29.86 million
Optionable: Not Optionable
Beta: 0.48

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

Mr. David Coman (Age 53)
CEO & Director
Comp: $796.13k
Ms. Christine A. Pellizzari J.D. (Age 55)
Chief Legal & Human Resources Officer and Secretary
Comp: $521.58k
Ms. Darcy Forman (Age 47)
Chief Delivery Officer
Comp: $550.58k
Mr. Mike Zaranek (Age 52)
Chief Financial Officer
Irena Lambridis
VP and Head of Quality Assurance & Compliance
Ms. Margie Gimbel Kooman
Vice President of Marketing & Communications
Mr. Drew Bustos
Chief Strategy & Marketing Officer
Mr. Jonathan Cotliar M.D. (Age 51)
Chief Medical Officer
Comp: $486.6k
Mr. Michael Shipton (Age 51)
Chief Commercial Officer
Mr. Tyler Van Horn
VP of Corporate Strategy & Chief of Staff

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

SNCE Stock Analysis - Frequently Asked Questions

Should I buy or sell Science 37 stock right now?: 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Science 37 in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" SNCE shares.
View SNCE analyst ratings or view top-rated stocks.
What is Science 37's stock price target for 2024?: 1 brokers have issued 12-month target prices for Science 37's stock. Their SNCE share price targets range from $1.00 to $1.00. On average, they anticipate the company's share price to reach $1.00 in the next twelve months. This suggests a possible upside of 300.0% from the stock's current price.
View analysts price targets for SNCE or view top-rated stocks among Wall Street analysts.
How have SNCE shares performed in 2023?: Science 37's stock was trading at $0.4152 at the beginning of 2023. Since then, SNCE stock has decreased by 39.8% and is now trading at $0.25.
View the best growth stocks for 2023 here.
Are investors shorting Science 37?: Science 37 saw a increase in short interest in November. As of November 15th, there was short interest totaling 1,630,000 shares, an increase of 50.9% from the October 31st total of 1,080,000 shares. Based on an average daily trading volume, of 209,600 shares, the days-to-cover ratio is currently 7.8 days. Currently, 2.1% of the shares of the stock are short sold.
View Science 37's Short Interest.

When is Science 37's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, March 4th 2024.
View our SNCE earnings forecast.
How were Science 37's earnings last quarter?: Science 37 Holdings, Inc. (NASDAQ:SNCE) issued its earnings results on Tuesday, November, 7th. The company reported ($0.08) earnings per share for the quarter. The company had revenue of $14.89 million for the quarter, compared to the consensus estimate of $14.70 million. Science 37 had a negative net margin of 206.86% and a negative trailing twelve-month return on equity of 83.09%.
Who are Science 37's major shareholders?: Science 37's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Boston Partners (1.19%) and Kent Lake Capital LLC (0.91%).
View institutional ownership trends.
How do I buy shares of Science 37?: Shares of SNCE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:SNCE) was last updated on 12/4/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial